RXRX icon

Recursion Pharmaceuticals

7.99 USD
+0.33
4.31%
Updated Feb 12, 12:12 PM EST
1 day
4.31%
5 days
-1.84%
1 month
18.55%
3 months
5.41%
6 months
32.50%
Year to date
10.82%
1 year
-26.97%
5 years
-74.47%
10 years
-74.47%
 

About: Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

Employees: 500

0
Funds holding %
of 6,831 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

102% more repeat investments, than reductions

Existing positions increased: 107 | Existing positions reduced: 53

0% more funds holding in top 10

Funds holding in top 10: 6 [Q2] → 6 (+0) [Q3]

2% less first-time investments, than exits

New positions opened: 45 | Existing positions closed: 46

2% less funds holding

Funds holding: 268 [Q2] → 263 (-5) [Q3]

10% less capital invested

Capital invested by funds: $1.91B [Q2] → $1.73B (-$183M) [Q3]

17.34% less ownership

Funds ownership: 110.7% [Q2] → 93.35% (-17.34%) [Q3]

42% less call options, than puts

Call options by funds: $11.4M | Put options by funds: $19.8M

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$10
25%
upside
Avg. target
$10.50
31%
upside
High target
$11
38%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Needham
Gil Blum
18% 1-year accuracy
30 / 171 met price target
38%upside
$11
Buy
Reiterated
6 Feb 2025
Keybanc
Scott Schoenhaus
58% 1-year accuracy
21 / 36 met price target
25%upside
$10
Overweight
Maintained
8 Jan 2025

Financial journalist opinion

Based on 9 articles about RXRX published over the past 30 days

Neutral
Zacks Investment Research
17 hours ago
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider
Recursion Pharmaceuticals (RXRX) closed at $7.66 in the latest trading session, marking a +0.13% move from the prior day.
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider
Neutral
GlobeNewsWire
6 days ago
Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference
SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) reported 12 month data from the Phase 2 study (SYCAMORE) of REC-994, the first industry sponsored Phase 2 trial completed in Cerebral Cavernous Malformations (CCM). The Company announced in September 2024 that the signal-finding study met its primary endpoint .
Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference
Neutral
Zacks Investment Research
1 week ago
Recursion Pharmaceuticals (RXRX) Ascends While Market Falls: Some Facts to Note
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $7.25, representing a +0.14% change from its previous close.
Recursion Pharmaceuticals (RXRX) Ascends While Market Falls: Some Facts to Note
Positive
24/7 Wall Street
1 week ago
Cathie Wood's Top Biotech Plays for February
Don't look now, but Cathie Wood of Ark Invest is fresh off an impressive comeback year, with her broader basket of disruptive technology funds posting high double-digit percentage returns.
Cathie Wood's Top Biotech Plays for February
Positive
The Motley Fool
1 week ago
3 Monster Stocks to Hold for the Next 10 Years
Are you looking for high-odds, high-growth prospects to buy and hold for the next decade? That's a tall order to be sure.
3 Monster Stocks to Hold for the Next 10 Years
Positive
Zacks Investment Research
2 weeks ago
Recursion Pharmaceuticals (RXRX) Moves 8.9% Higher: Will This Strength Last?
Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Recursion Pharmaceuticals (RXRX) Moves 8.9% Higher: Will This Strength Last?
Positive
The Motley Fool
3 weeks ago
2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025
Investors looking for stocks that could make dramatic moves in a short, defined time frame will want to turn their attention toward two innovative drugmakers. A couple of stocks in the volatile biopharmaceutical industry are poised to soar by the end of March.
2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025
Positive
The Motley Fool
3 weeks ago
Is Recursion Pharmaceuticals Stock a Buy?
Everything touching artificial intelligence (AI) is hot right now, so it's no surprise that the biotech Recursion Pharmaceuticals (RXRX -0.31%) could be positioned to ride the ongoing wave of hype to great heights. Between its AI-first approach to designing new drugs and its positioning as a valuable collaborator for other companies, the company is worth paying attention to at a minimum.
Is Recursion Pharmaceuticals Stock a Buy?
Negative
Zacks Investment Research
3 weeks ago
Recursion Pharmaceuticals (RXRX) Rises Yet Lags Behind Market: Some Facts Worth Knowing
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $6.42, marking a +1.58% move from the previous day.
Recursion Pharmaceuticals (RXRX) Rises Yet Lags Behind Market: Some Facts Worth Knowing
Positive
Zacks Investment Research
1 month ago
Does Recursion Pharmaceuticals (RXRX) Have the Potential to Rally 27.96% as Wall Street Analysts Expect?
The mean of analysts' price targets for Recursion Pharmaceuticals (RXRX) points to a 28% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Does Recursion Pharmaceuticals (RXRX) Have the Potential to Rally 27.96% as Wall Street Analysts Expect?
Charts implemented using Lightweight Charts™